Literature DB >> 8628602

Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.

S M Arpadi1, L E Markowitz, A L Baughman, K Shah, H Adam, A Wiznia, G Lambert, J Dobroszycki, J L Heath, W J Bellini.   

Abstract

OBJECTIVES: The goals of this study were to evaluate the proportion of previously vaccinated human immunodeficiency virus (HIV) type 1-infected children with detectable postvaccination measles antibody; to assess risk factors for vaccine failure; and to evaluate the response to reimmunization.
METHODS: A total of 81 perinatally HIV-infected children receiving medical care in the Bronx, New York who had previously received measles vaccine were enrolled. The Centers for Disease Control and Prevention (CDC) HIV class, lymphocyte subsets, and measles antibody were determined upon enrollment. Additional data abstracted from medical records included dates and number of prior measles vaccinations and CDC HIV class at the time of vaccination. Measles antibody was determined by microneutralization enzyme-linked immunosorbent assay (ELISA).
RESULTS: The median age at time of study was 42 months (range, 9 to 168 months). Overall, 58 (72%) subjects had detectable measles antibody (microneutralization ELISA titer > 1:5). Children studied within 1 year of vaccination were more likely to have detectable measles antibody than children evaluated more than 1 year after vaccination (83% vs 52%, P < .01). The proportion of children with detectable measles antibody was higher among children with no or moderate immunosuppression compared to those with severe immunosuppression when immune status was based on CD4%. Children vaccinated at 6 to 11 months of age appeared to have a higher proportion of detectable measles antibody than those who received a first measles vaccination after age 1. Only 1 (14%) of 7 previously vaccinated children who were seronegative or had very low titers experienced a four-fold rise in measles antibody when reimmunized.
CONCLUSION: These results support current recommendations to vaccinate HIV-infected children against measles. The proportion of children with detectable measles antibody among vaccinated HIV-infected children is considerably lower than in vaccinated healthy children. HIV-infected children may respond better to measles vaccine when it is administered before the first birthday. From our limited data it appears that reimmunization of previously vaccinated HIV-infected children with moderate to severe immunosuppression does not result in an antibody recall response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628602

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

1.  Measles vaccination: Weighing the benefits and risks of a live viral vaccine for HIV-infected children.

Authors: 
Journal:  Can J Infect Dis       Date:  1996-07

Review 2.  Immunization of HIV infected children.

Authors:  Jagdish Chandra; Dinesh Yadav
Journal:  Indian J Pediatr       Date:  2012-02-10       Impact factor: 1.967

Review 3.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Measles and Rubella Seroprevalence Among HIV-infected and Uninfected Zambian Youth.

Authors:  Catherine G Sutcliffe; Kelly Searle; Hellen K Matakala; Michelle P Greenman; Kaitlin Rainwater-Lovett; Philip E Thuma; William J Moss
Journal:  Pediatr Infect Dis J       Date:  2017-03       Impact factor: 2.129

5.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

6.  Updated Recommendations for the Use of Varicella and MMR Vaccines In HIV-Infected Individuals: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-16

7.  Risk Factors for Measles in HIV-infected Children and Adolescents in Botswana.

Authors:  Kathleen E Wirth; Elizabeth R Wolf; David M Goldfarb; Ari Ho-Foster; Michael Tolle; Christina Jacovides; Brianna Kirk; Mamiki Chise; Andrew P Steenhoff
Journal:  Pediatr Infect Dis J       Date:  2015-10       Impact factor: 2.129

8.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

Review 9.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

Review 10.  Optimal timing of routine vaccination in HIV-infected persons.

Authors:  Heidi M Crane; Shireesha Dhanireddy; H Nina Kim; Christian Ramers; Timothy H Dellit; Mari M Kitahata; Robert D Harrington
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.